221 related articles for article (PubMed ID: 24913988)
1. Utility of FDG-PET in clinical neuroendocrine prostate cancer.
Spratt DE; Gavane S; Tarlinton L; Fareedy SB; Doran MG; Zelefsky MJ; Osborne JR
Prostate; 2014 Aug; 74(11):1153-9. PubMed ID: 24913988
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer.
Nuñez R; Macapinlac HA; Yeung HW; Akhurst T; Cai S; Osman I; Gonen M; Riedel E; Scher HI; Larson SM
J Nucl Med; 2002 Jan; 43(1):46-55. PubMed ID: 11801702
[TBL] [Abstract][Full Text] [Related]
4. Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer.
Morris MJ; Akhurst T; Osman I; Nunez R; Macapinlac H; Siedlecki K; Verbel D; Schwartz L; Larson SM; Scher HI
Urology; 2002 Jun; 59(6):913-8. PubMed ID: 12031380
[TBL] [Abstract][Full Text] [Related]
5. Adenocarcinoma Prostate With Neuroendocrine Differentiation: Potential Utility of 18F-FDG PET/CT and 68Ga-DOTANOC PET/CT Over 68Ga-PSMA PET/CT.
Parida GK; Tripathy S; Datta Gupta S; Singhal A; Kumar R; Bal C; Shamim SA
Clin Nucl Med; 2018 Apr; 43(4):248-249. PubMed ID: 29474196
[TBL] [Abstract][Full Text] [Related]
6. Metabolic activity in bone metastases of breast and prostate cancer were similar as studied by
Pietrzak A; Czepczynski R; Wierzchoslawska E; Cholewinski W
Hell J Nucl Med; 2017; 20(3):237-240. PubMed ID: 29177262
[TBL] [Abstract][Full Text] [Related]
7.
Shen K; Yu M; Ji Y; Zhou X; Liu B; Zhang W; Su R; Qi J; Wang Q; Xue W
Prostate; 2023 Sep; 83(12):1167-1175. PubMed ID: 37189301
[TBL] [Abstract][Full Text] [Related]
8. Multitarget Molecular Imaging in Metastatic Castration Resistant Adenocarcinoma Prostate Cancer with Therapy Induced Neuroendocrine Differentiation.
Vargas Ahumada J; González Rueda SD; Sinisterra Solís FA; Pitalúa Cortés Q; Torres Agredo LP; Miguel JR; Scavuzzo A; Soldevilla-Gallardo I; Álvarez Avitia MA; Sobrevilla N; García Pérez FO
Diagnostics (Basel); 2022 Jun; 12(6):. PubMed ID: 35741197
[TBL] [Abstract][Full Text] [Related]
9. Positron emission tomography and bone metastases.
Fogelman I; Cook G; Israel O; Van der Wall H
Semin Nucl Med; 2005 Apr; 35(2):135-42. PubMed ID: 15765376
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of baseline [18F] fluorodeoxyglucose positron emission tomography and 99mTc-MDP bone scan in progressing metastatic prostate cancer.
Meirelles GS; Schöder H; Ravizzini GC; Gönen M; Fox JJ; Humm J; Morris MJ; Scher HI; Larson SM
Clin Cancer Res; 2010 Dec; 16(24):6093-9. PubMed ID: 20975102
[TBL] [Abstract][Full Text] [Related]
11. Comparison of bone scintigraphy and 18F-FDG PET-CT in a prostate cancer patient with osteolytic bone metastases.
Ozcan Kara P; Kara T; Kara Gedik G; Sari O; Sahin O
Rev Esp Med Nucl; 2011; 30(2):94-6. PubMed ID: 21342722
[TBL] [Abstract][Full Text] [Related]
12. FDG PET-CT demonstration of metastatic neuroendocrine tumor of prostate.
Liu Y
World J Surg Oncol; 2008 Jun; 6():64. PubMed ID: 18565231
[TBL] [Abstract][Full Text] [Related]
13. C11-acetate and F-18 FDG PET for men with prostate cancer bone metastases: relative findings and response to therapy.
Yu EY; Muzi M; Hackenbracht JA; Rezvani BB; Link JM; Montgomery RB; Higano CS; Eary JF; Mankoff DA
Clin Nucl Med; 2011 Mar; 36(3):192-8. PubMed ID: 21285676
[TBL] [Abstract][Full Text] [Related]
14. Miscellaneous cancers (lung, thyroid, renal cancer, myeloma, and neuroendocrine tumors): role of SPECT and PET in imaging bone metastases.
Chua S; Gnanasegaran G; Cook GJ
Semin Nucl Med; 2009 Nov; 39(6):416-30. PubMed ID: 19801221
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Value of
Zhang J; Liu Q; Singh A; Schuchardt C; Kulkarni HR; Baum RP
J Nucl Med; 2020 Nov; 61(11):1560-1569. PubMed ID: 32169914
[TBL] [Abstract][Full Text] [Related]
16. MIB-1 Index-Stratified Assessment of Dual-Tracer PET/CT with
Sampathirao N; Basu S
J Nucl Med Technol; 2017 Mar; 45(1):34-41. PubMed ID: 28154019
[TBL] [Abstract][Full Text] [Related]
17. Detection of the Prostate Cancer Bone Metastases: Is It Feasible to Compare 18F-fluorocholine PET/CT, 18F-fluorodeoxyglucose PET/CT and 99mTc-methyl Diphosphonate Bone Scintigraphy?
Pietrzak AK; Czepczynski R; Wierzchoslawska E; Cholewinski W
Urol J; 2018 Sep; 15(5):242-247. PubMed ID: 29681049
[TBL] [Abstract][Full Text] [Related]
18. Prospective Study of Serial
Peterson LM; O'Sullivan J; Wu QV; Novakova-Jiresova A; Jenkins I; Lee JH; Shields A; Montgomery S; Linden HM; Gralow J; Gadi VK; Muzi M; Kinahan P; Mankoff D; Specht JM
J Nucl Med; 2018 Dec; 59(12):1823-1830. PubMed ID: 29748233
[TBL] [Abstract][Full Text] [Related]
19. Prospective evaluation of the clinical utility of 18-fluorodeoxyglucose PET CT scanning in patients with von hippel-lindau-associated pancreatic lesions.
Sadowski SM; Weisbrod AB; Ellis R; Patel D; Alimchandani M; Quezado M; Millo C; Venzon DJ; Nilubol N; Linehan WM; Kebebew E
J Am Coll Surg; 2014 May; 218(5):997-1003. PubMed ID: 24661849
[TBL] [Abstract][Full Text] [Related]
20. A Feasibility Study Showing [
Behr SC; Aggarwal R; Seo Y; Aparici CM; Chang E; Gao KT; Tao DH; Small EJ; Evans MJ
Mol Imaging Biol; 2016 Dec; 18(6):946-951. PubMed ID: 27184068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
